EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effectiveness and safety of the recombinant zoster vaccine in individuals ≥50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study

Emily Rayens, Lina S Sy, Lei Qian, Jun Wu, Bradley K Ackerson, Yi Luo, Yanjun Cheng, Antony T Lin, Zendi Solano, Justine De Jesus, Britta Amundsen, Ana Florea und 6 weitere

Annals of the Rheumatic Diseases · 2025

DOI: 10.1016/j.ard.2025.01.045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2025. Verfasst von Emily Rayens und 17 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente Southern California, Pasadena, CA, USA. Electronic address: emily.x.rayens@kp.org. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Herpes Zoster, Herpes Zoster Vaccine, Neuralgia, Postherpetic. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kaiser Permanente Southern California, GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidHerpes ZosterHerpes Zoster VaccineNeuralgia, PostherpeticVaccine EfficacyHumansMiddle AgedFemaleMaleRetrospective StudiesAgedVaccines, SyntheticCase-Control Studies

Substanzen

Herpes Zoster VaccineVaccines, Synthetic

Autor:innen und Institutionen

  • Kaiser Permanente Southern California, Pasadena, CA, USA. Electronic address: emily.x.rayens@kp.org.
  • Kaiser Permanente Southern California, Pasadena, CA, USA.
  • GSK, Rockville, MD, USA.
  • Kaiser Permanente Southern California, Pasadena, CA, USA; Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.

Förderung

  • Kaiser Permanente Southern California
  • GlaxoSmithKline

Zitieren

APA

Rayens, E., Sy, L. S., Qian, L., Wu, J., Ackerson, B. K., Luo, Y., Cheng, Y., Lin, A. T., Solano, Z., De Jesus, J., Amundsen, B., Florea, A., Ku, J. H., Chmielewski-Yee, E., Oraichi, D., Seifert, H., Yun, H., & Tseng, H. F. (2025). Effectiveness and safety of the recombinant zoster vaccine in individuals ≥50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.01.045

Vancouver

Rayens E, Sy LS, Qian L, Wu J, Ackerson BK, Luo Y, et al. Effectiveness and safety of the recombinant zoster vaccine in individuals ≥50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study. Annals of the Rheumatic Diseases. 2025. doi:10.1016/j.ard.2025.01.045

BibTeX
@article{Rayens2025,
  author = {Rayens, Emily and Sy, Lina S and Qian, Lei and Wu, Jun and Ackerson, Bradley K and Luo, Yi and Cheng, Yanjun and Lin, Antony T and Solano, Zendi and De Jesus, Justine and Amundsen, Britta and Florea, Ana and Ku, Jennifer H and Chmielewski-Yee, Elizabeth and Oraichi, Driss and Seifert, Harry and Yun, Huifeng and Tseng, Hung Fu},
  title = {Effectiveness and safety of the recombinant zoster vaccine in individuals ≥50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study},
  journal = {Annals of the Rheumatic Diseases},
  year = {2025},
  doi = {10.1016/j.ard.2025.01.045}
}
Kostenlos starten →